Michael Gelband’s Lipocine LPCN Stock Holding History

Michael Gelband’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-689	Closed	-$12K	–	2461
2021 Q4	$12K	Sell	689 -644	-48%	-$12K	﹤0.01%	2098
2021 Q3	$25K	Buy	+1,333	New	+$29.4K	﹤0.01%	2010

Other funds holding LPCN

AWA

Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Michael Gelband's LPCN Position: Q1 2022 in Review

Michael Gelband sold out of Lipocine (LPCN) in Q1 2022, closing a stake of 689 shares — an estimated $12K sold.

Michael Gelband first reported a position in LPCN in Q3 2021 and held it in 2 quarters. The position peaked at $25K in Q3 2021. 44 funds tracked by Wall St. Rank hold LPCN as of Q1 2022.

Michael Gelband reported no remaining Lipocine position as of Q1 2022 after selling out during the quarter.
Michael Gelband sold 689 Lipocine shares in Q1 2022, an estimated $12K.
Michael Gelband first reported a position in Lipocine in Q3 2021 and held it in 2 quarters.
Michael Gelband's Lipocine position peaked at $25K in Q3 2021.
44 funds tracked by Wall St. Rank held Lipocine as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.